AstraZeneca’s Plan To Spur Brilinta Sales Is On Track, CEO Says
This article was originally published in The Pink Sheet Daily
Executive Summary
Plans to jumpstart growth of Brilinta are working, AstraZeneca said during the company’s second quarter sales and earnings call Aug. 1. Investors may not see the results until the end of the year, however.